Results 151 to 160 of about 7,662,476 (212)

Bevacizumab plus nab-paclitaxel and platinum as second-line therapy for driver-gene-negative non-squamous non-small cell lung cancer after immunochemotherapy: A prospective single-arm single-centre study. [PDF]

Clin Transl Med
Lin Y, Yu Y, Hu Z, Wei C, Wang Z, Zhang Y, Wu Z, Yu B, Zhao X, Yu H, Wu X, Wang H, Wang J.   +12 more
europepmc   +1 more source

An upside to chronic inflammation? Starvation reconfigures immune pathways in Manduca sexta, producing chronic inflammation that may help defend against bacterial infection. [PDF]

PLoS One
Adamo SA, Burns MR, Englehardt MH, Grabtchak A, Kearney R, Martin CAE, Richmond MR.   +6 more
europepmc   +1 more source

Integration of Nanotechnology with ctDNA: New Advances for Monitoring Neoadjuvant Chemotherapy. [PDF]

Int J Nanomedicine
Wang Y, Kong J, Tian R.
europepmc   +1 more source

Advances in antibody-mediated rejection of renal allografts. [PDF]

Front Immunol
Song B, Sun J, Hu C, Liu X.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

PLASMA CONCENTRATION OF AMITRIPTYLINE AND CLINICAL RESPONSE

Lancet, The, 1972
Abstract Plasma amitriptyline and nortriptyline concentrations were measured in fifteen depressive patients who were treated with 150 mg. amitriptyline daily for 6 weeks. There was a considerable variation in plasma levels of both amitriptyline and its metabolite nortriptyline in individual patients.
R A Braithwaite, Alec Coppen, A Coppen
exaly   +3 more sources

Plasma Nortriptyline and Clinical Response

Australian & New Zealand Journal of Psychiatry, 1975
(1975). Plasma Nortriptyline and Clinical Response. Australian and New Zealand Journal of Psychiatry: Vol. 9, No. 4, pp. 249-253.
B, Davies, G, Burrows, B, Scoggins
openaire   +2 more sources